🟡 Regulatory Alert
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 defect notification for Gabapentin Relonchem 50mg/ml Oral Solution after manufacturer Relonchem Limited reported the presence of particles in some bottles of the medication. The defect was identified following a customer complaint, according to the MHRA alert issued on its official medicines alert portal.
Key takeaways
- Relonchem Limited identified particles in bottles of Gabapentin Relonchem 50mg/ml Oral Solution following customer complaint
- The MHRA classified the defect as Class 4, the most serious category indicating risk of serious adverse health consequences
- Affected batches have been identified; healthcare professionals and patients should check batch numbers and report any concerns to their pharmacy or GP
MHRA medicines defect classification system
Classes ranked by severity and patient risk — UK regulatory framework
Source: MHRA Guidance on Medicines Defect Reporting | GMJ News
What triggered the alert
Relonchem Limited, the manufacturer of Gabapentin Relonchem 50mg/ml Oral Solution, reported to the MHRA that particles had been detected inside some bottles of the medication. The discovery came via a customer complaint, according to the company’s notification. Gabapentin is a widely used anticonvulsant and neuropathic pain medication prescribed across the United Kingdom.
The presence of foreign particles in an oral liquid formulation raises safety concerns, as ingestion of such material could potentially cause harm depending on the particle composition, size, and patient factors. The MHRA’s assignment of a Class 4 classification indicates the agency determined the defect poses a realistic potential for serious adverse health consequences.
Regulatory response and patient safety measures
The MHRA’s medicines alert system has notified healthcare professionals, pharmacy chains, and hospital pharmaceutical services of the defect. The alert includes specific batch numbers affected by the contamination, enabling healthcare providers to identify stock and remove it from distribution. Patients currently taking affected batches of the medication have been advised to consult their pharmacy or general practitioner for guidance.
Class 4 defect notifications require immediate communication to the healthcare supply chain. The MHRA typically requests that manufacturers implement recall procedures, conduct root-cause analysis, and provide information about the extent of the defect. Relonchem Limited is expected to cooperate fully with regulatory oversight and investigation into how the contamination occurred.
Implications for prescribers and patients
General practitioners, neurologists, and pain management specialists prescribing gabapentin in oral solution form should verify patient batches against the MHRA alert list. Patients taking Gabapentin Relonchem 50mg/ml Oral Solution should check their bottle’s batch number against the affected batches listed in the official notification. Those with affected batches should not discontinue the medication without medical guidance, as abrupt cessation of gabapentin can cause withdrawal symptoms; instead, they should contact their pharmacy or GP immediately for alternative supply arrangements.
The incident underscores the importance of pharmaceutical manufacturing quality control systems and the value of post-market surveillance mechanisms such as customer complaint reporting. The MHRA maintains a public database of all medicines alerts, enabling healthcare professionals and patients to stay informed of emerging safety issues affecting their medications.
Particles observed in bottles of Gabapentin Relonchem 50mg/ml Oral Solution have triggered a Class 4 defect alert from the UK Medicines and Healthcare products Regulatory Agency, the highest severity classification.
— MHRA Medicines Alert, 2024
What this means
Frequently asked questions
What is a Class 4 medicines defect?
According to the MHRA’s classification system, a Class 4 defect represents the most serious category of pharmaceutical contamination or manufacturing fault. It indicates that use of the defective medicine may result in serious adverse health consequences or death. Class 4 alerts require immediate action including product recall and healthcare provider notification.
How do I know if my gabapentin is affected?
The MHRA alert specifies the affected batch numbers. Locate your bottle’s batch number (typically printed on the label) and compare it against the list provided in the official MHRA alert. Your pharmacist can also check your records and confirm whether your supply is affected.
Is it safe to continue taking my gabapentin while waiting for a replacement?
If your gabapentin is not from an affected batch, continue taking it as prescribed. If it is affected, consult your GP or pharmacist before making any changes; they may provide temporary alternative supply or switching guidance. Abrupt discontinuation of gabapentin carries risks of withdrawal symptoms including anxiety, insomnia, and rebound pain, so medical guidance is essential.
The incident reflects the critical role of pharmaceutical regulatory agencies in protecting public health through post-market surveillance and rapid response to safety signals. The MHRA’s swift issuance of a Class 4 alert demonstrates the effectiveness of the UK’s medicines safety reporting system, though the underlying contamination underscores the continued importance of rigorous manufacturing quality assurance. Patients and healthcare professionals are advised to remain alert to official MHRA medicines alerts and report any suspected adverse effects or quality defects through the Yellow Card scheme or directly to their healthcare provider.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
